← Leaderboards
Manu Jain
Northwestern University
$1,174,021
Attributed
$1,174,021
Total exposure
13
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $214.2K · FY2005–24$250K$187.5K$125K$62.5K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$1,174,021 · 11
VA$0 · 2
By mechanism
R34$642,615 · 1
M01$531,406 · 10
I01$0 · 2
Top collaborators
- Gr Scott Budinger12 shared
Most similar at Northwestern University
Same institution · by research overlap
- Gr Scott Budinger$22,037,096
- Brian Joseph Mitchell$7,945,720
- Thomas Hope$67,101,837
- Robert M Judd$11,520,625
- Daniel Kim$10,161,271
Others in their field
Top investigators on “Lung”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$372,040,227
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$201,818,043
- Walter John Curran · Thomas Jefferson University$112,093,071
Research focus
LungFibroblastsBleomycinInjuryFibrosisPulmonary FibrosisPreventProteinsGene ExpressionAsbestosAlveolarGenesMouse ModelResponseTherapeutic TargetMediatingLung DevelopmentNovel TherapeuticsBaseReportingResearch PersonnelAwardInhibitor/AntagonistInnovation
Grant awards (29)
Mitochondrial metabolism as a therapeutic target in pulmonary fibrosis$0
I01 · FY2024 · VA · contact PI
Assessing the role of metabolism in monocyte to macrophage differentiation in pulmonary fibrosis$0
I01 · FY2022 · VA
Assessing the role of metabolism in monocyte to macrophage differentiation in pulmonary fibrosis$0
I01 · FY2021 · VA
Assessing the role of metabolism in monocyte to macrophage differentiation in pulmonary fibrosis$0
I01 · FY2020 · VA
Assessing the role of metabolism in monocyte to macrophage differentiation in pulmonary fibrosis$0
I01 · FY2019 · VA
Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis$214,205
R34 · FY2017 · HL · contact PI
The Role of Mitochondrial Reactive Oxygen Species in TGF-Beta Signaling$0
I01 · FY2017 · VA
Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis$214,205
R34 · FY2016 · HL · contact PI
The Role of Mitochondrial Reactive Oxygen Species in TGF-Beta Signaling$0
I01 · FY2016 · VA
Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis$214,205
R34 · FY2015 · HL · contact PI
The Role of Mitochondrial Reactive Oxygen Species in TGF-Beta Signaling$0
I01 · FY2015 · VA
The Role of Mitochondrial Reactive Oxygen Species in TGF-Beta Signaling$0
I01 · FY2014 · VA
Mechanisms of proteasomal regulation of fibrosis$0
I01 · FY2013 · VA
Mechanisms of proteasomal regulation of fibrosis$0
I01 · FY2012 · VA
Mechanisms of proteasomal regulation of fibrosis$0
I01 · FY2011 · VA
MEDIATORS OF MYOFIBROBLAST DIFFERENTIATION IN ARDS$20,107
M01 · FY2007 · RR · contact PI
PSEUDOMONAS AERUGINOSA TYPE III SECRETION IN CYSTIC FIBROSIS$14,166
M01 · FY2007 · RR · contact PI
THE ROLE OF PROCOLLAGEN 1 AND TGF-BETA 1 IN CYSTICFIBROTIC PULMONARY DISEASE$6,398
M01 · FY2007 · RR · contact PI
PSEUDOMONAS AERUGINOSA TYPE III SECRETION IN CYSTIC FIBROSIS$136,421
M01 · FY2006 · RR · contact PI
PSEUDOMONAS AERUGINOSA TYPE III SECRETION IN CYSTIC FIBROSIS$17,739
M01 · FY2006 · RR · contact PI
THE ROLE OF PROCOLLAGEN 1 AND TGF-BETA 1 IN CYSTICFIBROTIC PULMONARY DISEASE$3,379
M01 · FY2006 · RR · contact PI
MEDIATORS OF MYOFIBROBLAST DIFFERENTIATION IN ARDS$422
M01 · FY2006 · RR · contact PI
PSEUDOMONAS AERUGINOSA TYPE III SECRETION IN CYSTIC FIBROSIS$120,645
M01 · FY2005 · RR
PSEUDOMONAS AERUGINOSA TYPE III SECRETION IN CYSTIC FIBROSIS$32,233
M01 · FY2005 · RR
MECHANISMS OF INCREASED DEAD-SPACE IN ARDS$16,577
M01 · FY2005 · RR
Pseudomonas aeruginosa Type III Secretion in Cystic Fibrosis$162,017
M01 · FY2004 · RR
Mechanisms of Increased Dead-Space in ARDS$1,302
M01 · FY2004 · RR
Phase II study to evaluate DMP777 in Adults with Cystic Fibrosis$0
M01 · FY2001 · RR
Phase II study to evaluate DMP777 in Adults with Cystic Fibrosis$0
M01 · FY2000 · RR